Register Login

Liquidia Corporation (LQDA)

(10% Negative) LIQUIDIA CORPORATION (LQDA) Announces Delay in million Trials for Liquidia Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 11:32 a.m.

    📋 LIQUIDIA CORPORATION (LQDA) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 06:30:35

    Event Type: Clinical Trial Update

    Event Details:

    Liquidia Corporation (LQDA) Announces Clinical Trial Update Liquidia Corporation (LQDA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: million, year
    • Diseases/Conditions: Liquidia
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: YUTREPIA Net Sales and Corporate Update
    • Updated Timeline: June 2025, full-year 2025

    🔬 Clinical Development Pipeline (LIQUIDIA CORPORATION):

    Product Type Development Stage Therapeutic Area Source
    Ticagrelor 60mg DRUG Phase PHASE4 Coronary Artery Disease ClinicalTrials.gov
    Prasugrel 5mg DRUG Phase PHASE4 Coronary Artery Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Liquidia Corporation
    • CIK: 0001819576
    • Ticker Symbol: LQDA
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories